Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Vipul Jairath, Keith Chan, Karen Lasch, Sam Keeping, Christian Agboton, Aimee Blake & Haridarshan Patel. (2021) Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Review of Gastroenterology & Hepatology 15:6, pages 711-722.
Read now
Read now
Aditya Sardesai, Axel Dignass, Peter Quon, Sandra Milev, Joseph C. Cappelleri, Agnes Kisser, Irene Modesto & Puza P. Sharma. (2021) Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. Journal of Medical Economics 24:1, pages 279-290.
Read now
Read now
Abhishek Varu, Florence R. Wilson, Peter Dyrda, Maureen Hazel, Brian Hutton & Chris Cameron. (2019) Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study. Current Medical Research and Opinion 35:5, pages 733-756.
Read now
Read now
Sean Stern, Alexandra J. Ward, Catherine Saint-Laurent Thibault, Fernando Camacho, Elham Rahme, Dominik Naessens, Guy Aumais, Edmond-Jean Bernard, Raymond Bourdages, Albert Cohen, Pierre Pare & Peter Dyrda. (2018) Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of Medical Economics 21:1, pages 27-37.
Read now
Read now
Mathurin Flamant, Stephane Paul & Xavier Roblin. (2017) Golimumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 17:7, pages 879-886.
Read now
Read now
Anne S. Strik, Sophie E. Berends, Ron A. Mathôt, Geert R. D’Haens & Mark Löwenberg. (2017) Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 11:5, pages 401-406.
Read now
Read now
Nikola Mitrev & Rupert W. Leong. (2017) Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opinion on Drug Safety 16:3, pages 303-317.
Read now
Read now
Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi & Alessandro Armuzzi. (2016) Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug, Healthcare and Patient Safety 8, pages 1-7.
Read now
Read now
Saurabh Kedia, Vineet Ahuja & Govind K. Makharia. (2016) Golimumab for moderately to severely active ulcerative colitis. Expert Review of Clinical Pharmacology 9:10, pages 1273-1282.
Read now
Read now
A. S. Strik, S. J. A. Bots, G. D’Haens & M. Löwenberg. (2016) Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 9:3, pages 429-439.
Read now
Read now
Articles from other publishers (39)
Xinqiao Chu, Yaning Biao, Chengjiang Liu, Yixin Zhang, Chenxu Liu, Ji-zheng Ma, Yufeng Guo & Yaru Gu. (2023) Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. BMC Gastroenterology 23:1.
Crossref
Crossref
Tia Goss Sawhney, Angela Dobes & Sirimon O’Charoen. (2023) Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data. Crohn's & Colitis 360 5:4.
Crossref
Crossref
Brigida Barberio, David J. Gracie, Christopher J. Black & Alexander C. Ford. (2023) Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis. Digestive and Liver Disease.
Crossref
Crossref
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton & Anna Schwendeman. (2023) Physicochemical characterization and functionality comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria® (golimumab). International Journal of Pharmaceutics 635, pages 122646.
Crossref
Crossref
Renato Sablich, Maria Teresa Urbano, Marco Scarpa, Federico Scognamiglio, Alberto Paviotti & Edoardo Savarino. (2023) Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis. Scientific Reports 13:1.
Crossref
Crossref
Sang Hyoung Park, Byong Duk Ye & Suk-Kyun Yang. (2022) Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?. Gut and Liver 16:1, pages 138-140.
Crossref
Crossref
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoît Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler & Benjamin Misselwitz. (2022) Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therapeutic Advances in Gastroenterology 15, pages 175628482210741.
Crossref
Crossref
Pascal Juillerat, Maude Martinho Grueber, Roseline Ruetsch, Giulia Santi, Marianne Vuillèmoz & Pierre Michetti. (2022) Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?. Current Research in Pharmacology and Drug Discovery 3, pages 100104.
Crossref
Crossref
Victoria Tatiana Kronsten, Michael J. Colwill, Shadab Nayeemuddin, Jimmy K. Limdi, Christian Selinger, Glyn Scott, Lulia Al‐Hillawi, Shayon Salehi, Paul Blaker, Guy Chung‐Faye, Alexandra J. Kent, Patrick Dubois & Bu Hayee. (2021) A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. GastroHep 3:4, pages 229-235.
Crossref
Crossref
Brigida Barberio, Fabiana Zingone, Leonardo Frazzoni, Renata D’Incà, Maria Chiara Maccarone, Matteo Ghisa, Davide Massimi, Greta Lorenzon & Edoardo Vincenzo Savarino. (2021) Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. Digestive Diseases 39:1, pages 16-24.
Crossref
Crossref
Moto Kitayama, Yuko Akazawa, Daisuke Yoshikawa, Shuntaro Higashi, Tomohito Morisaki, Hidetoshi Oda, Maho Ikeda, Yujiro Nakashima, Maiko Tabuchi, Keiichi Hashiguchi, Kayoko Matsushima, Naoyuki Yamaguchi, Hisayoshi Kondo, Kazuhiko Nakao & Fuminao Takeshima. (2020) Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Scientific Reports 10:1.
Crossref
Crossref
Silvio Danese, Gionata Fiorino & Laurent Peyrin-Biroulet. (2020) Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 18:6, pages 1280-1290.e1.
Crossref
Crossref
Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou & Ryuichi Iwakiri. (2019) Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics 38:1, pages 69-84.
Crossref
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Crossref
A. B. Demina. (2019) Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis. Modern Rheumatology Journal 13:4, pages 110-115.
Crossref
Crossref
Fabio Vieira Teixeira, Eduardo Garcia Vilela, Aderson Omar Mourão Cintra Damião, Andrea Vieira, Idblan Carvalho De Albuquerque, José Miguel Luz Parente, Júlio Maria Fonseca Chebli, Orlando Ambrogini Junior, Rogerio Saad Hossne & Sender Jankiel Miszputen. (2019) Ulcerative colitis - treatment with biologicals. Revista da Associação Médica Brasileira 65:4, pages 547-553.
Crossref
Crossref
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini & Francesca Rogai. (2018) Golimumab in inflammatory bowel diseases: present and future scenarios. Clinical Journal of Gastroenterology 12:1, pages 1-9.
Crossref
Crossref
Jay J. H. Park, Ofir Harari, Ellie Siden, Michael Zoratti, Louis Dron, Noor-E Zannat, Richard T. Lester, Kristian Thorlund & Edward J. Mills. (2020) Interventions to improve birth outcomes of pregnant women living in low- and middle-income countries: a systematic review and network meta-analysis. Gates Open Research 3, pages 1657.
Crossref
Crossref
Jay J. H. Park, Ofir Harari, Ellie Siden, Michael Zoratti, Louis Dron, Noor-E Zannat, Richard T. Lester, Kristian Thorlund & Edward J. Mills. (2019) Interventions to improve birth outcomes of pregnant women living in low- and middle-income countries: a systematic review and network meta-analysis. Gates Open Research 3, pages 1657.
Crossref
Crossref
Ehsan Motaghi, Masoumeh Ghasemi-Pirbaluti & Mohsen Zabihi. (2019) Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison. Pharmacological Research 139, pages 120-125.
Crossref
Crossref
Sophie E. Berends, Anne S. Strik, Mark Löwenberg, Geert R. D’Haens & Ron A. A. Mathôt. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics 58:1, pages 15-37.
Crossref
Crossref
Paschalis Paschos, Anastasia Katsoula, Georgia Salanti, Olga Giouleme, Eleni Athanasiadou & Apostolos Tsapas. (2018) Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Alimentary Pharmacology & Therapeutics 48:11-12, pages 1174-1185.
Crossref
Crossref
Sara Renna, Filippo Mocciaro, Marco Ventimiglia, Rosalba Orlando, Fabio Salvatore Macaluso, Maria Cappello, Walter Fries, Marco Mendolaro, Antonino Carlo Privitera, Concetta Ferracane, Valentina Pisana, Antonio Magnano, Dario Pluchino, Gaetano Inserra, Giuseppe Scarpulla, Serena Garufi, Antonio Carroccio, Sebastiano Siringo, Roberto Di Mitri, Mario Cottone & Ambrogio Orlando. (2018) A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Digestive and Liver Disease 50:12, pages 1292-1298.
Crossref
Crossref
Karen Smith, Su Golder, Abeed Sarker, Yoon Loke, Karen O’Connor & Graciela Gonzalez-Hernandez. (2018) Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. Drug Safety 41:12, pages 1397-1410.
Crossref
Crossref
Jimmy K Limdi. (2018) Golimumab for ulcerative colitis: adding perspective to the pursuit. Frontline Gastroenterology 9:3, pages 232-233.
Crossref
Crossref
Robert Hodgson, Matthew Walton, Mousumi Biswas, Teumzghi Mebrahtu & Nerys Woolacott. (2017) Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 36:4, pages 387-398.
Crossref
Crossref
Tomer Greener, Karen Boland, A Hillary Steinhart & Mark S Silverberg. (2018) The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 12:4, pages 458-464.
Crossref
Crossref
Gülay Büyükköroğlu & Behiye Şenel. 2018. Omics Technologies and Bio-Engineering. Omics Technologies and Bio-Engineering
353
389
.
Chris CameronEmmanuel EwaraFlorence R. WilsonAbhishek VaruPeter DyrdaBrian HuttonMichael Ingham. (2017) The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. Medical Decision Making 37:8, pages 894-904.
Crossref
Crossref
Mark T. Osterman & Gary R. Lichtenstein. (2017) Infliximab vs Adalimumab for UC: Is There A Difference?. Clinical Gastroenterology and Hepatology 15:8, pages 1197-1199.
Crossref
Crossref
Yuga Komaki, Fukiko Komaki, Dejan Micic, Akihiro Yamada, Yasuo Suzuki & Atsushi Sakuraba. (2017) Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta‐analysis. Journal of Gastroenterology and Hepatology 32:6, pages 1143-1151.
Crossref
Crossref
E. J. Mao, G. S. Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet & A. N. Ananthakrishnan. (2017) Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics 45:1, pages 3-13.
Crossref
Crossref
S. Ndoja & H. Lima. 2017. Current Developments in Biotechnology and Bioengineering. Current Developments in Biotechnology and Bioengineering
71
95
.
Calen A. Steiner, Emily P. Whitfield, Jeremy Adler & Peter D. R. Higgins. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
401
416
.
S. Renna, E. Orlando, F. S. Macaluso, M. Maida, M. Affronti, M. Giunta, C. Sapienza, G. Rizzuto, R. Orlando, M. Dimarco, M. Cottone & A. Orlando. (2016) Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Alimentary Pharmacology & Therapeutics 44:3, pages 310-311.
Crossref
Crossref
Ashwin N. Ananthakrishnan, Andrew Cagan, Tianxi Cai, Vivian S. Gainer, Stanley Y. Shaw, Guergana Savova, Susanne Churchill, Elizabeth W. Karlson, Isaac Kohane, Katherine P. Liao & Shawn N. Murphy. (2016) Comparative Effectiveness of Infliximab and Adalimumab in Crohnʼs Disease and Ulcerative Colitis. Inflammatory Bowel Diseases 22:4, pages 880-885.
Crossref
Crossref
Caroline Meyer Olesen, Mehmet Coskun, Laurent Peyrin-Biroulet & Ole Haagen Nielsen. (2016) Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & Therapeutics 159, pages 110-119.
Crossref
Crossref
Shmuel Odes. (2016) Refractory Ulcerative Proctitis—A Brief Review. Open Journal of Gastroenterology 06:10, pages 239-248.
Crossref
Crossref
Martin Bürger, Carsten Schmidt, Niels Teich & Andreas Stallmach. (2015) Medical Therapy of Active Ulcerative Colitis. Visceral Medicine 31:4, pages 236-245.
Crossref
Crossref